Clinical Trials Logo
  1. Home
  2. IGA Nephropathy
  3. NCT04905212

A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy

IgA Nephropathy Clinical Trial

Official title:
A Phase 2, Randomized, Double-Blind, Multicenter Study of Telitacicept for Injection (RC18) With an Optional Open Label Extension in Subjects With IgA Nephropathy

Clinical Trial Summary

This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical study with an optional open label extension to evaluate the safety and efficacy of Telitacicept for Injection (RC18) in the treatment of IgA nephropathy.

Clinical Trial Description

IgA nephropathy is a kidney disease in which IgA, a protein meant to defend the body against foreign invaders, accumulates in the kidneys and damages them. This study will seek to determine the safety and efficacy of Telitacicept for Injection (RC18) in the treatment of IgA nephropathy. The study is composed of 4 parts: a screening period, a double-blind treatment period, an optional open label extension, and a follow-up period. Subjects with confirmed IgA nephropathy will be enrolled and randomized 1:1:1 to Telitacicept 160 mg, Telitacicept 240 mg, or placebo (10 per arm). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04905212
Study type Interventional
Source RemeGen Co., Ltd.
Contact
Status Terminated
Phase Phase 2
Start date November 4, 2021
Completion date November 9, 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05016323 - A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy. Phase 2
Withdrawn NCT02433236 - Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy Phase 2
Recruiting NCT02231125 - Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy Phase 4
Completed NCT01502579 - An Observational Study of IgA Nephropathy: Pathological Variants and Clinical Data N/A
Not yet recruiting NCT01203007 - Diet Intervention in Food Sensitive Patients With IgA Nephropathy N/A
Terminated NCT01129557 - Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease Phase 4
Completed NCT00657059 - Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN) Phase 3
Recruiting NCT04684745 - Open-Label Extension Study of BION-1301 in IgA Nephropathy Phase 2
Completed NCT03719443 - First in Human Study to Assess Safety of VIS649 in Healthy Subjects Phase 1
Completed NCT02112838 - Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy Phase 2
Withdrawn NCT02052219 - BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy Phase 3
Completed NCT00767221 - Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study Phase 2
Recruiting NCT04438603 - The Applicaiton of Immune Repertoire in the Diagnosis and Disease Monitoring of IgA Nephropathy
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Terminated NCT04042623 - Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy Phase 2
Recruiting NCT03633864 - Fecal Microbiota Transplantation for Refractory IgA Nephropathy Phase 2
Not yet recruiting NCT06454110 - Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN) Phase 2
Recruiting NCT02954419 - IgA Nephropathy Biomarkers Evaluation Study (INTEREST)
Recruiting NCT03001947 - IgA Nephropathy Registration Initiative of High Quality (INSIGHT)
Completed NCT01224028 - A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients Phase 2